Stryker (SYK) Gets a Hold Rating from Needham
In a report released today, Michael Matson from Needham maintained a Hold rating on Stryker (SYK). The company’s shares closed last Thursday at $200.20.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 9.6% and a 60.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Stryker has an analyst consensus of Moderate Buy, with a price target consensus of $216.38.
See today’s analyst top recommended stocks >>
Stryker’s market cap is currently $75.15B and has a P/E ratio of 35.40. The company has a Price to Book ratio of -4447.35.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.